Wout A P Breeman
Overview
Explore the profile of Wout A P Breeman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Konijnenberg M, Breeman W, de Blois E, Chan H, Boerman O, Laverman P, et al.
EJNMMI Res
. 2015 Jun;
4(1):47.
PMID: 26116111
Background: Targeted radionuclide therapy with high-energy beta-emitters is generally considered suboptimal to cure small tumours (<300 mg). Tumour targeting of the CCK2 receptor-binding minigastrin analogue PP-F11 was determined in a...
2.
Marsouvanidis P, Melis M, de Blois E, Breeman W, Krenning E, Maina T, et al.
Cancer Biother Radiopharm
. 2014 Oct;
29(9):359-67.
PMID: 25286347
Introduction: Gastrin-releasing peptide receptors (GRPR) and GRP-derived analogs have attracted attention due to high receptor expression in frequently occurring human neoplasia. The authors recently synthesized a series of GRPR-affine peptide...
3.
Ocak M, Helbok A, Rangger C, Peitl P, Nock B, Morelli G, et al.
Eur J Nucl Med Mol Imaging
. 2011 Apr;
38(8):1426-35.
PMID: 21528387
Purpose: Stability of radiolabelled cholecystokinin 2 (CCK2) receptor targeting peptides has been a major limitation in the use of such radiopharmaceuticals especially for targeted radionuclide therapy applications, e.g. for treatment...
4.
Schroeder R, Muller C, Reneman S, Melis M, Breeman W, de Blois E, et al.
Eur J Nucl Med Mol Imaging
. 2010 Feb;
37(7):1386-96.
PMID: 20182713
Purpose: Prostate-specific antigen (PSA)-based screening for prostate cancer (PC) has dramatically increased early diagnosis. Current imaging techniques are not optimal to stage early PC adequately. A promising alternative to PC...
5.
Schroeder R, de Visser M, van Weerden W, de Ridder C, Reneman S, Melis M, et al.
Int J Cancer
. 2009 Oct;
126(12):2826-34.
PMID: 19876914
Human prostate cancer (PC) overexpresses the gastrin-releasing peptide receptor (GRPR). Radiolabeled GRPR-targeting analogs of bombesin (BN) have successfully been introduced as potential tracers for visualization and treatment of GRPR-overexpressing tumors....
6.
de Jong M, Breeman W, Kwekkeboom D, Valkema R, Krenning E
Acc Chem Res
. 2009 May;
42(7):873-80.
PMID: 19445476
Molecular imaging plays an essential role in balancing the clinical benefits and risks of radionuclide-based cancer therapy. To effectively treat individual patients, careful assessment of biodistribution, dosimetry, and toxicity is...
7.
Froberg A, de Jong M, Nock B, Breeman W, Erion J, Maina T, et al.
Eur J Nucl Med Mol Imaging
. 2009 Mar;
36(8):1265-72.
PMID: 19266197
Purpose: Cholecystokinin 2 (CCK-2) receptor overexpression has been demonstrated in a high percentage of medullary thyroid carcinomas (MTC). Analogous to somatostatin receptors, CCK-2 receptors might be viable targets for radionuclide...
8.
Maina T, Nock B, Cordopatis P, Bernard B, Breeman W, van Gameren A, et al.
Eur J Nucl Med Mol Imaging
. 2006 Mar;
33(7):831-40.
PMID: 16568203
Purpose: The aim of this study was to evaluate [(99m)Tc]Demotate 2 ([(99m)Tc-N(4) (0-1),Asp(0),Tyr(3)]octreotate) as a candidate for in vivo imaging of sst(2)-positive tumours and to compare it with [(111)In]DOTA-tate ([(111)In-DOTA(0),Tyr(3)]octreotate)....
9.
Capello A, Krenning E, Bernard B, Breeman W, Erion J, de Jong M
J Nucl Med
. 2006 Jan;
47(1):122-9.
PMID: 16391196
Unlabelled: Tumor-induced angiogenesis can be targeted by RGD (Arg-Gly-Asp) peptides, which bind to alpha(v)beta(3)-receptors upregulated on angiogenic endothelial cells. RGD-containing peptides are capable of inducing apoptosis through direct activation of...
10.
de Jong M, Breeman W, Valkema R, Bernard B, Krenning E
J Nucl Med
. 2005 Jan;
46 Suppl 1:13S-7S.
PMID: 15653647
Unlabelled: Peptide receptor-targeted radionuclide therapy of somatostatin receptor-expressing tumors is a promising application of radiolabeled somatostatin analogs. Suitable radionuclides are (90)Y, a pure, high-energy beta-emitter (2.27 MeV), and (177)Lu, a...